Why Some Med Students Learn Cadavers' Names

At one Indiana medical school, students are taught to think of their cadavers as their first patients and may even meet their families. Critics contend this may cross an ethical line and put students in an uncomfortable position.

Charles Dharapak / AP

First year medical students dissect a cadaver at a gross anatomy lab at Georgetown University Medical Center in Washington, Nov. 5, 2009.

Kyle Gospodarek expected to feel nervous about seeing a dead body up close on his first day of anatomy lab. He steeled himself for the smell a pungent blend of latex, embalming fluid and something indescribable whose odor would cling to his clothes for days but he never imagined he would have to get in touch with the cadavers family. Ill be honest: when I first heard about what we were doing, I was weirded out, he says. I didnt know what to say to them.

At Indiana University Northwest, an IU branch campus located in Gary, Ind., anatomy professor Ernest Talarico instructs his medical students to probe beyond the nerves and muscles of the bodies lying on their examination tables and think of the cadavers as their first patients. We ask students to use the name of the patient out of respect and to acknowledge that this was a person, he says. His students also typically exchange letters with family members to glean more information about their patients medical histories, hobbies and interests. They may even meet the family in person at the conclusion of the course during a memorial service held in the laboratory.

(MORE: Can Doctors Have Work-Life Balance? Medical Students Discuss)

The annals of medical school training are filled with sordid tales of students taking glam shots with corpses or assigning unflattering nicknames to cadavers. When Talarico was in medical school, he remembers his classmates calling one cadaver Salty because of the tattoo of the naked woman on his chest. These people had lives and names, he says, and to use other names disrespects them.

Talarico believes his approach not only helps students be more respectful of the individuals who have given their bodies to science but also prepares them to act as empathetic clinicians when theyre faced with the cold, hard medical decisions theyll have to make in their careers. He has no formal data to prove his approach gets better results, but anecdotally, the students say they feel better prepared to address patients as individuals and consider their feelings. As one student, Adam Harker, explains: I think it translates into better post-op care and compliance.

While Talarico has won praise from many of the individuals involved in the program, hes also raised concerns among critics who question the ethics of his teaching technique. When donated bodies are passed on to medical schools, the institutions are usually only given the basics the donors name, gender, age and immediate cause of death. The name of the donor is typically not shared with students, and students do not usually interact with the donors next of kin.

(MORE: Doctors Salaries: Who Earns the Most and the Least?)

Here is the original post:
Why Some Med Students Learn Cadavers' Names

UM Med School Planning 800 Layoffs

MIAMI (CBSMiami) TheUniversity of Miami medical school says it has already started laying off employees. And while the school did tell the state that 800 positions would be affected, the dean of the school says he hopes that fewer than 800 people will be laid off.

Dean Pascal Goldschmidt told reporters that no medical care givers would lose their jobs. The layoffs will impact those in administrative and research positions.

This is really the last resort, said Goldschmidt. We have done everything to solve this, reducing our expenses and now the number of employees.

The UM school of medicine has about 8,000 employees.

TheUMschool of medicinehad filed a WARN notice with the state that the layoff date would be July 31st. Goldschmidt said the layoffs would be staggered over a period of time.

Dr. Obi Ekwenna is the chief resident in Urology and in his fifth year at the school. Hes concerned not only for those losing jobs, but also for the patients.

It is tough, people their jobs and being laid off, Dr. Ekwenna said. Its very sad, not only for the community, but for the patients. Ultimately, they are the ones affected the most.

The move comes just weeks after UM President Donna Shalala told employees that significant cuts were being planned at the medical school. Shalala said a huge drop in funding for research and clinical care, along with a sharp cutback in payments from the Jackson Health System, and the Great Recession were all factors in the decision.

According to the Herald, payments to UM from Jackson have dropped by $16 million in the last two years.

I think the economic downturn is affecting our country as a whole, trickling down to hospitals and universities as a whole, Dr. Ekwenna said.

Originally posted here:
UM Med School Planning 800 Layoffs

Call for medical school split review

12 May 2012 Last updated at 06:38 ET

Ministers are to be asked by Plymouth City Council to review a decision to divide a medical school.

Plymouth and Exeter universities announced in January that they wanted to separate the Peninsula College of Medicine and Dentistry.

Councillors are concerned about the potential impact of the de-merger on the economy and healthcare provision.

The universities said separate schools in each city would result in places for more students.

The college currently has places for 200 medical and 64 dentistry students.

The de-merger would see a medical and dentistry school in Plymouth and a medical school in Exeter.

The council decision to write to ministers comes after Plymouth University announced its leadership team for the city's new school, due to open in 2013, earlier this month.

The city council had requested a 12-week consultation into the de-merger proposals.

A Conservative councillor and former member of the now Labour council's health scrutiny panel, Dr David Salter, said: "We do not want these universities to pull apart without us being sure on behalf of our citizens that healthcare will continue to be good in our area."

Read more:
Call for medical school split review

UM medical school to lay off up to 800

University of Miami Health System layoffs

University of Miami President Donna E. Shalala talks about layoffs at the University of Miami Health System, including the medical school. Shalala spoke to the Miami Herald Tuesday, May 8, 2012.

Chuck Fadely / Miami Herald Staff

More information

Up to 800 people will lose their jobs under a major restructuring at the University of Miami medical school, President Donna Shalala said Tuesday.

State budget cuts, less research money, lower compensation from insurers and cutbacks in payments by Jackson Health System made the changes necessary, Shalala said during a meeting at the Miami Herald.

Its not a great situation, Shalala said, but at the end of the day, well be a much stronger healthcare system of a much higher quality because we will be able to reinvest in healthcare delivery. ... Weve moved this institution to new heights. The world is changing beneath our feet.

Laid-off workers are being notified this month, Shalala said. A notice UM filed with the state Tuesday announced the university would cut 800 jobs by July 31, but Shalala said the final number is likely to be lower. The cutback is the largest by any employer in the state since the medical schools campus neighbor, Jackson, announced 920 layoffs in February.

The UM reduction amounts to 8 percent of the medical centers 10,000-person workforce. Shalala said no doctors or nurses who provide clinical care would be affected. The cuts announced Tuesday come after 182 temporary workers were laid off in late March.

Most of the UM layoffs are concentrated in research and administration as the university centralizes services to serve the entire enterprise. About 150 people who schedule appointments will lose their jobs in various departments as that service is centralized. About 150 in research administration and 110 researchers will also be let go, according to the letter UM filed with the state.

See more here:
UM medical school to lay off up to 800

UM medical school plans to lay off 800 people

MIAMI (AP) - University of Miami officials say the medical school is planning to lay off as many as 800 people.

UM President Donna Shalala told The Miami Herald (http://bit.ly/Ju2nBc ) Tuesday that the move will better prepare the school for the future.

Shalala says state budget cuts, reduced funds for research, cuts in compensation from insurers and cutbacks in payments by Jackson Health System have made the changes necessary. She says said some medical school employees will be let go, but may be rehired after restructuring of departments. Some will retire and others will accept severance packages. Shalala says no doctors or nurses who provide clinical care would be affected.

Those laid off will be notified this month. The reduction amounts to 8% of the medical center's 10,000-person workforce.

Information from: The Miami Herald, http://www.herald.com

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Originally posted here:
UM medical school plans to lay off 800 people

UM's Medical School Laying Off 800 Workers

UM Doctors Use Telemedicine to Continue Care In Iraq

For the past 10 years Jackson Memorial Hospital's Ryder Trauma Center has been the medical training site for the US Army _ training that was put to use in Iraq.

UM Gets Technology for New Heart Valves

The Zeego is one of the new cutting edge tools at the UM Hospitals new $2.5 million Hybrid Cath Lab.

The University of Miami's medical school on Tuesday started laying off up to 800 workers, NBC 6 learned.

The layoffs at the Leonard M. Miller School of Medicine will be completed by May 31, the end of UM's fiscal year. A Worker Adjustment and Retraining Notification was posted to floridajobs.org.

A UM spokeswoman told NBC 6 that no clinical staff workers who directly deal with patients are affected and that some workers will be rehired in restructured positions.

In a letter sent to employees April 24, Miller's Dean Dr. Pascal Goldschmidt announced the reductions, calling them "painful but essential."

"There are no easy choices due to decreases in government funding, health insurance changes, and the financial struggles of our valued partners at Jackson Memorial Hospital, and it is clear that part of our strengthening must involve rightsizing our organization and reducing our workforce," Goldschmidt said. "To remain focused on providing better care to our community, we are reducing administrative duplication and unfunded research so we may deploy more resources to our clinical operations."

Goldschmidt told NBC 6 that "patient care is entirely untouched."

View post:
UM's Medical School Laying Off 800 Workers

BSD Medical Reports Hyperthermia Clinical Study on Pancreatic Cancer Highlighted at Society of Thermal Medicine …

SALT LAKE CITY--(BUSINESS WIRE)--

BSD Medical Corporation (NASDAQ: BSDM - News) ("Company" or "BSD") (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, reported today that an important Phase III clinical study, hyperthermia in combination with chemotherapy for the treatment of pancreatic cancer patients, was the subject of a press release issued by The Society of Thermal Medicine (STM) (http://psfebus.allenpress.com/eBusSFTM/). STM highlighted initiation of the Hyperthermia European Adjuvant Trial (HEAT) during its 29th Annual Conference, which was held in Portland, Ore. The randomized, multicenter, Phase III study, sponsored by the Munich Groshadern University Medical School (UMS) and the European Society for Hyperthermic Oncology, compares hyperthermia with chemotherapy (gemcitabine plus cisplatin) to chemotherapy (gemcitabine) alone. Patients are randomized following standard surgical resection of the tumor. The study is open for enrollment of 350 patients and has already enrolled the first three patients. Patient enrollment is expected to proceed quickly. The principal investigators are Rolf D. Issels, MD PhD, and Katharina Lechner, MD, from the Munich Grosshadern UMS, Munich, Germany.

The following clinical sites will initially participate in the clinical study: Munich Grosshadern UMS, Munich, Klinik Bad Trissl, Oberaudorf, Red Cross Hospital, Munich, UMS Dsseldorf, UMS Erlangen and UMS Tbingen, all Germany. These sites all utilize the BSD-2000 Hyperthermia System.

Pancreatic cancer is one of the deadliest and most difficult to treat cancers and is the fourth leading cause of cancer-related death in the U.S. and throughout the world. There will be an estimated 44,000 Americans and 60,000 Europeans diagnosed with pancreatic cancer during 2012. The median survival is approximately 6 months for patients with metastatic disease and 10 months for patients with locally advanced disease. Median survival after 5 years is <5% of all patients. Advanced pancreatic cancer patients currently have few treatment options.

About the Society for Thermal Medicine

The Society for Thermal Medicine (STM) was founded in 1986 as a professional society to significantly improve treatment outcomes by advancing the science, development and application of thermal therapy. STM is a premier, international scientific forum for fostering interaction and innovation in the study of biological, physical and medical applications of thermal therapy for cancer and other diseases. STM promotes rapid dissemination of exciting scientific breakthroughs in thermal medicine in order to expedite the translation of both basic and applied research to the clinic for the immediate benefit of patients. STM also sponsors high quality forums for education of medical professionals in the practice of thermal medicine.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSDs product lines include both hyperthermia and ablation treatment systems. BSDs hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSDs microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Companys products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at http://www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Excerpt from:
BSD Medical Reports Hyperthermia Clinical Study on Pancreatic Cancer Highlighted at Society of Thermal Medicine ...

University of Pittsburgh Medical School Professor Secures Funding for Beating the BluesUS Research Study

PITTSBURGH, May 3, 2012 /PRNewswire/ -- Funding for a four-year, $2.6-million research study that could impact how certain mental health conditions are managed in primary care settings has been secured by a University of Pittsburgh School of Medicine professor.

The research study is designed to evaluate the effectiveness of Beating the BluesUS, an online cognitive behavioral therapy program that is sold and supported by U Squared Interactive, LLC. Bruce L. Rollman, M.D., M.P.H., professor of medicine, psychiatry, and Clinical and Translational Science at Pitt's School of Medicine, received funding for the study from the National Institute of Mental Health (NIMH).

"The study findings are likely to impact the way that certain mental health conditions are managed in primary care," said Dr. Rollman. "Online computerized CBT programs such as Beating the BluesUS are new and evolving technologies that can improve patient access to personalized, convenient and effective mental health interventions."

The study will measure the effectiveness of Beating the BluesUS (alone, and in combination with an Internet support group), and compare it to treatment as usual for depression and anxiety within primary care. The research study will involve 700 patients, ages 18 to 75, who will be referred to the trial by physicians at a dozen or more UPMC-affiliated primary care practices located across western Pennsylvania.

"We also hope our study will focus further attention on the emerging field of `e-mental health' by other U.S. investigators," Dr.Rollman said.

CBT is a form of psychotherapy that teaches individuals how to change the way they think in order to improve the way they feel and how they respond to problems. It is a widely used and effective modality for people with anxiety and depression.

Over 80 million Americans suffer from a mood or anxiety disorder at some point in their lives and these conditions are associated with substantial reductions in quality of life and an increase in the use of health services.

"Beating the BluesUS's delivery of computerized CBT has demonstrated proven efficacy," said Neal Ryan, M.D., a professor of Psychiatry at Pitt's School of Medicine and a U Squared Interactive board member. "This is important to the health care of our patients in decreasing barriers to access, providing a cost-effective approach to effective management of depression and anxiety and, for some, being a powerful adjunct to various treatment modalities."

U Squared Interactive, LLC, is a joint venture between the UPMC Insurance Services Division and Ultrasis UK Ltd., a London-based company. Beating the Blues is Ultrasis's flagship product for anxiety and depression in the United Kingdom.

Full details of the study can be found at http://clinicaltrials.gov/ct2/show/study/NCT01482806?term=rollman&rank=1.)

Read the original post:
University of Pittsburgh Medical School Professor Secures Funding for Beating the BluesUS Research Study

University Hospitals Case Medical Center's Harrington Discovery Institute Launches Grant Program to Accelerate Drug …

CLEVELAND, May 1, 2012 /PRNewswire/ --University Hospitals Case Medical Center's Harrington Discovery Institute has announced a grant competition that serves as a nationwide search for physician-scientists seeking support to accelerate their promising drug discoveries into novel treatments for patients. The Harrington Scholar-Innovator grants will create a bold new pathway for these researchers, who are inspired by their patients, to discover and create novel therapies.

Lacking government and investor funding and partnerships with pharmaceutical companies, many researchers have drug discoveries that are unable to advance into clinical development.

Aimed at addressing this critical issue, the UH Harrington Discovery Institute, launched in February, is the not-for-profit academic medical engine of The Harrington Discovery and Development Project: a first-of-its-kind, $250 million initiative that also includes a mission-aligned, for-profit development company. Aligning these entities for the first time at an academic medical center provides a comprehensive model to advance discoveries into development and to create novel drugs and therapies for patient care.

"This is an important step forward for our exciting initiative, which is to create a new model for drug discovery and development in academia," says the Institute's Director, Jonathan Stamler, MD. "Supporting physician-scientists through the Harrington Scholar-Innovator grants in their early research will address the funding and expertise gaps that exist, thereby helping these researchers to move their clinical discoveries forward."

The annual grant competition, run by UH Harrington Discovery Institute, will offer to support the translation of research from laboratory to early development stages. Up to ten physician-scientists each year will be supported with Harrington Scholar-Innovator grants of up to $200,000 over two years. Guiding the selection of the grant winners are seven prominent physician-scientists who have joined the UH Harrington Discovery Institute Scientific Advisory Board.

"Beyond the grant, we will be there every step of the way for entrepreneurial physician-scientists," adds Dr. Stamler, who is also Director of the Institute for Transformative Molecular Medicine at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine. "Physician-scientists will be able to tap into a peer network of innovators and mentors within the UH Harrington Discovery Institute's infrastructure to support their discovery efforts."

The grant application is open to physician-scientists at accredited academic medical centers, research institutions, and universities in the United States. Applicants must have a doctorate in medicine, and must demonstrate exceptional promise as physician-scientists. The grant will recognize the importance of innovation to the mission of the physician-scientist. Applications found at UHHarringtonDiscoveryInstitute.org are due by 5 p.m. ET, August 1, 2012, and recipients will be announced in the spring of 2013 at the UH Harrington Discovery Institute's inaugural scientific symposium.

"The Harrington Scholar-Innovator Grants are game-changers for physician-scientists across the country who face a number of obstacles in advancing their breakthroughs through commercialization," said Andrew Schafer, MD, chairman of medicine at Weill Cornell Medical College in New York and physician-in-chief at New York-Presbyterian Hospital. "UH Harrington Discovery Institute has identified these obstacles funding, time pressures and lack of expert guidance and has created a model specifically designed to reduce, or even eliminate, their effects on therapeutic innovation."

Dr. Stamler concludes, "These grants are intended to ensure that physician-scientists can advance their discoveries and that their careers that are dedicated to furthering the mission: To Heal. To Teach. To Discover. This is University Hospitals Case Medical Center's mission, and mirrors that of major academic medical centers and dedicated physician-scientists throughout the country."

# # #

Originally posted here:
University Hospitals Case Medical Center's Harrington Discovery Institute Launches Grant Program to Accelerate Drug ...

ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System

MINNEAPOLIS, May 1, 2012 /PRNewswire/ --ProUroCare Medical Inc. (PUMD.OB), provider of proprietary medical imaging products, announced today it has received clearance from the U.S. Food & Drug Administration (FDA) for its ProUroScan prostate mechanical imaging (PMI) system. The approval paves the way for men and their families to receive high-resolution visual documentations as an aid in detecting prostate abnormalities that were previously detected by digital rectal examination (DRE). The ProUroScan system constructs color 2D and 3D "maps" of the prostate in real-time that, when in agreement with a DRE finding, can be permanently stored in electronic records for future analysis and comparison. ProUroCare's patented tactile elasticity imaging technology, which uses a handheld pressure-sensing rectal probe and sophisticated image construction software to produce its prostate maps, represents a new imaging modality distinct from traditional ultrasound imaging.

The company plans to introduce the technology in 2012 to a limited number of top U.S. medical care centers in key major metropolitan markets. With assistance from Minneapolis investment firm Cherry Tree & Associates, LLC, ProUroCare has been actively seeking a strategic corporate partner with a strong sales and in-service support presence in the urologic market to fully commercialize its technology.

"This is a major milestone for the company, for physicians looking for more assurance and documentation in their evaluations and for men eager for more information to assess and make decisions about their prostate health," said Rick Carlson, CEO of ProUroCare Medical. "A color image can go a long way in documenting a person's prostate condition, and this development puts us one step closer to supplementing other screening measures with a helpful, high quality visual aid that can be referred and compared to over time."

As a standard of care, the American Urological Association (AUA) currently recommends that beginning at age 40, men receive a DRE and a prostate specific antigen (PSA) blood test in their yearly physical, yet data from community-based studies suggest the positive predictive values of DRE and PSA combined achieve only a 56 percent predictive value. Furthermore, neither test creates a physical or visual record of the prostate. The ProUroScan system is being introduced as an adjunctive technology to a DRE for physicians to use to further clarify and document abnormalities associated with the prostate gland.

"Having a visual aid of irregularities can be so helpful to physicians and patients, particularly in the area of prostate care where decision-making is often difficult," said Dr. Robert Weiss, a urologic oncologist with the Cancer Institute of New Jersey and a faculty member at Robert Wood Johnson Medical School who used the ProUroScan technology as part of its clinical trial process. "The quality and resolution of the images are excellent, providing an immensely valuable supplement to the DRE, where physicians must rely on a gloved finger to feel for changes in the size and shape of the gland."

The prostate imaging system's FDA 510(k) was first submitted by ProUroCare's development partner Artann Laboratories, Inc. and later processed in accordance with the de novo provisions accounted for in Section 513(f)(2) of the Federal Food, Drug and Cosmetic Act. The FDA filings were supported by data from a 2009 National Institute of Health and National Cancer Institute-supported clinical study of patients evaluated at five leading U.S. medical centers, as well as an earlier study conducted specifically at the Robert Wood Johnson Medical Center in New Brunswick, N.J.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. Based in Minneapolis, Minn., the company's stock trades on the OTCBB market.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the impact and timing of actions taken by the FDA and other regulatory agencies with respect to ProUroCare's products and business; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.

Go here to see the original:
ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System

Stanford professors propose 'lecture-less' medical school classes

Public release date: 2-May-2012 [ | E-mail | Share ]

Contact: Ruthann Richter richter1@stanford.edu 650-725-8047 Stanford University Medical Center

STANFORD, Calif. Dramatic changes are needed in medical student education, including a substantial reduction in the number of traditional lectures, according to a perspective piece to be published May 3 in the New England Journal of Medicine by two Stanford University professors.

Medical education has changed little in the past 100 years despite dramatic changes in the world of medicine, the explosion in biomedical information and the ever-growing complexity of the health-care system. The traditional lecture format persists even as class attendance is plummeting and as many complain that the current system is failing to produce compassionate, well-trained physicians.

"Students are being taught roughly the same way they were taught when the Wright brothers were tinkering at Kitty Hawk," write co-authors Charles Prober, MD, senior associate dean for medical education at the Stanford School of Medicine, and Chip Heath, PhD, professor of organizational behavior at the Stanford Graduate School of Business. (Heath and his brother, Dan, also authored a bestselling book, Made to Stick: Why Some Ideas Survive and Others Die.) In contemplating medical education reform, Prober reached out to Heath because a critical goal of any educational effort is to optimize the retention of lessons to increase their "stickiness."

In their perspective, titled "Lecture halls without lectures," Prober and Heath propose a new approach to teaching to make better use of the fixed amount of educational time available to train doctors.

"That's the vision that we want to chase: education that wrings more value out of the unyielding asset of time," the authors write. "Why would anyone waste precious class time on a lecture?"

Prober also has been working closely with Salman "Sal" Khan, the Silicon Valley-based online learning pioneer whose nonprofit effort, Khan Academy, is widely credited, in the words of Bill Gates, for having "turned the classroom and the world of education on its head." Prober and Heath's perspective piece proposes a Khan Academy-styled "flipped-classroom" model of teaching. Lecture content is packaged in 10- to 15-minute videos that are watched by the students at their own pace and as often as necessary to learn the material. Class time is then freed up for more interactive education, with greater emphasis on patients' clinical stories as a way to increase the relevance of the necessary scientific and medical knowledge.

"Teachers would be able to actually teach, rather than merely make speeches," the authors write.

The core biochemistry class at Stanford medical school was redesigned this year to follow this model. The instructors replaced the lecture-based format with short online videos made available to students. "Class time was used for interactive discussions of clinical vignettes that highlighted the biochemical bases of various diseases," the article said. "Student reviews of the course improved substantially from the previous year, and class attendance increased from 30 to 80 percent, even though class attendance was optional."

See more here:
Stanford professors propose 'lecture-less' medical school classes

Cannabis Science Makes Medical Moves at The 7th Patients Out of Time medical cannabis conference in Tucson at the …

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--

Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, was honored to be the Sponsor and an Exhibitor at the 7th national Patients Out of Time, medical cannabis conference in Tucson, Arizona. The conference was attended by patients, doctors, nurses, pharmacists, professors, supporters, and entrepreneurs of the medical cannabis industry. Our own Dr. Melamede presented patient's results that we have documented at http://www.cannabisscience.com.

The University of California, San Francisco School of Medicine (UCSF) is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuing medical education for physicians.Patients Out of Time is the only accredited CMEprogram to educate medical professionals about cannabis as a medicine. There were over 25 world-renowned doctors and scientists sharing and presenting the latest research advances asthe complexity of theendo-cannabinoid system continues to unfold. Please see the previous news release from April 17, 2012 at http://finance.yahoo.com/news/dr-robert-melamede-scheduled-speak-182800051.html

Speakers at the conference focused on the science and medicine of cannabinoids. Cannabis Science was overwhelmed, with great feedback by various representatives in the medical community. Prominent speakers included Dr. Robert Melamede, CEO and president of Cannabis Science; Dr. William Courtney of Cannabis Sciences scientific advisory board, and Dr. Andrew Weil, best selling author, speaker, and Integrative Medicine thought-leader. Talks covered specific ailments such as PTSD, cancer, and even drug addiction; research on cannabinoid science and medical applications, and law.Dr. Robert Melamede shared pictures show on our website. Cannabis Science helps cancer patients make informed choices regarding treatments. He also spoke as to the holistic nature by which the endocannabinoid system regulated homeostasis in all vertebrates from conception till death and therefore, why cannabis-based medicines are different from all others in their ability to help with so many illnesses.

Cannabis Science demonstrated a pre-release our multi-tiered, digital educational platform to be announcedin more detail laterthis week. Our novel platform will help to meet the ever-expanding interest incannabis that is coming from the medical communities as the almost miraculous medical benefits of cannabis emerge from the states that support medical marijuana. Our new educational platform (see below) willbring in revenues as we fill the emerging educational need of the medical community.Realistic cannabis education programs are not currently available in the professional schools that need them to end the disconnect between medical cannabis patients an their physicians.

At the conference the Cannabis Science booth collected data from attendees interested in Cannabis Science Stock and there was a lot of interest in our new branding platform.. Attendees were given PR Packets with CBIS information on cancer, Alzheimers, PTSD, aging, and heart disease. CBIS had attendees fill out a questionnaire to enter into a drawing for an iPad 3, a symbolic prize since Cannabis Science will launce our new digital education platform for Physicians, on the Apple iPad platform. Our congratulations to our conference iPad winner.

Andrew Pitsicalis, the Branding and Licensing Director for Cannabis Science, revealed the new digital platform and demonstrated the technology at the CBIS booth. Pitsicalis coordinated many interviews with Cannabis Planet TV, Arizona Clinics TV, The Phoenix Arizona Times, and local news and media. As a result, we had the honor to meet with a brain cancer survivor ofan extremely dangerous surgery.InDecember of last year, he had a second operation to try to reduce the large mass in his brain. With stage 4 cancer, he came to Cannabis Science to help us create awareness for other cancer patients worldwide so that they too might understand there is hope with cannabis. The patient had not been a previous cannabis user, and was amazed at the impact the plant had on him. In fact, it prevented him from taking his own life,when he was no longer able to cope withhaving multiple grand mal seizures daily. The patients close friend begged him to smoke cannabis. When he did, he stopped having seizures. He told us he drove 7 hours to meet Dr. Robert Melamede because he was watching his videos our website and YouTube and found hope. The patient wanted to go to the conference to meet him and other doctors and scientists attending the conference.

The Patients Out of Time charity benefit dinner included entertainment by Greta Gaines from her upcoming album Grassy Girl; a live and silent auction, and a guest appearance by Gigi Ganjay. Gretas information may be found at http://www.gretagaines.com, http://www.cannibuzz.com, and her reel at http://www.conlincasting.net/Gretareel/Greta_Gaines/Reel.html Greta Gaines is a client of Kaneabis (a Cannabis Science company).

If you would like to view information that Cannabis Science provided to the attendees of the conference, please visit our website.

Dr. Robert Melamede stated, Things have never been better for Cannabis Science and this was confirmed at the conference this past weekend. Not only were we part of an historic event with Patients Out of Time, the amount of consciousness and knowledge gained by everyone attending will shape the medicinal science of the industry going forward. Furthermore, our network of professionals increased substantially as we continue to grow the Cannabis Science business model. Most importantly, this conference was a success because it was about the patients,and we heard dramatic testimonials from them, It was all about doing the right things,with the right people, for the right reasons.

More:
Cannabis Science Makes Medical Moves at The 7th Patients Out of Time medical cannabis conference in Tucson at the ...

MAST medical school celebrates grand opening

HOMESTEAD, Fla. (WSVN) -- A South Florida high school dedicated to students pursuing medical careers is adding new features to their state-of-the-art facility.

Tuesday morning, faculty and students celebrated the grand opening of M.A.S.T. @ Homestead medical magnet school. It is the only school of its kind in South Florida.

Prior to its opening, Miami-Dade acquired the building, which once was a hospital, used $15 million to renovate it and enrolled students who are now studying medicine. "It's very educational, and it's really hands on," said student Sidney Sharpe.

"It's a very small environment. The teachers work one-on-one with you; it's very safe," said student Ian Carter. "It's a highly academic rigorous curriculum but an excellent school."

M.A.S.T is an acronym for Medical Academy for Science and Technology. This facility is the second in the State and one of just a few in the nation.

This year, about 250 students enrolled. Next year, about 450 students are expected to attend via lottery.

The magnet school's mission is to cultivate the next generation of health care professionals. It focuses on biomedical sciences, pharmaceutical sciences and physical therapy. "The top 100 jobs in the United States, you're going to see that 75 or 80 percent are in the medical field or medical background," said principal Greg Zawyer. "So, we're linked with all the hospitals, all the way down to Mercy and University of Miami, as well as Baptist Hospital in Homestead."

Miami-Dade Superintendent Alberto Carvahlo was also present at the school's ribbon-cutting ceremony. "The opportunity is for students to engage in internships at local hospitals and partnerships with FIU and the University of Miami, Nova and Miami Dade College, where they will serve in enrollment programs."

"We see that these are our future employees, they're future doctors, nurses and technologists and pharmacists," said Homestead Hospital CEO Bill Duquette.

The facility also conducts live surgeries via video conferences.

Original post:
MAST medical school celebrates grand opening

UM medical school to make cutbacks in May

CORAL GABLES, Fla. (AP) - University of Miami President Donna Shalala has put medical school staff on notice that "significant" cutbacks are coming.

Shalala announced the cuts in a letter to employees on Tuesday.

She says the reductions are necessary because of a number of "unprecedented factor" that include the economic downturn of 2008, decreased funding for research and clinical care and cuts in the Jackson Health System. She says the Jackson Health reductions have affected the school's finances.

The Miami Herald (http://bit.ly/I4JSlg ) reports Jackson Health, which has lost $419 million the past three years, cut its payments to the university by $16 million this year.

Shalala says the cuts will come in May. She did not provide details about how many employees may be laid off.

Information from: The Miami Herald, http://www.herald.com

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

See more here:
UM medical school to make cutbacks in May

Direct Flow Medical® Announces the Appointment of Chief Medical Officer, Charles Davidson, MD

SANTA ROSA, Calif.--(BUSINESS WIRE)--

Direct Flow Medical, Inc., a privately held, emerging medical device company focused on the next generation, minimally invasive implant to treat patients with heart valve disease announced the appointment of Charles Davidson, MD, as Chief Medical Officer. Dr. Davidson brings a wealth of knowledge to the organization, having spent over 20 years in interventional cardiology and medicine. He has also worked extensively in his career with medical device industry leaders and start-up companies.

Dr. Davidson currently is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Cardiac Catheterization Laboratory and Clinical Chief of Cardiology at Northwestern Memorial Hospital, Chicago, Illinois. His professional memberships include Fellow, American College of Cardiology, Fellow of the Society for Cardiac Angiography and Interventions and a Fellow membership with the Clinical Council, American Heart Association. Prior positions were held at Duke University Medical Center and Yale University School of Medicine. Dr. Davidsons experience in interventional cardiology and his extensive knowledge of cardiac care will be invaluable to Direct Flow Medical as we continue to expand our clinical trials and drive the future growth of the Company, commented Bernard Lyons, President and CEO of Direct Flow Medical. His longstanding thought leadership in the care of patients with cardiac disease, experience in novel interventional devices combined with his first-hand experience in the transcatheter aortic valve replacement (TAVR) procedures will help us achieve our clinical and market objectives. Simply, this is just a terrific addition to our existing team. The current clinical programs are actively recruiting patients outside the United States.

Dr. Davidsons connection with Direct Flow Medical began 3 years ago, when he first reviewed the early clinical data from the feasibility study and has been a key consultant to the DISCOVER CE Mark Study which was initiated late in 2011. About his newest affiliation with the organization, Dr. Davidson says, I am very impressed with the Direct Flow Medical device. This is a true, second generation device which is designed to allow for precise placement, conforms to the aortic valve anatomy, thereby virtually eliminating any paravalvular leaks. I look forward to working with the Direct Flow Medical Team and their outstanding group of clinical investigators and advisors to help bring this latest, unique innovation to fruition. The Direct Flow Medical device addresses one of the most important clinical issues in the TAVR Market aortic regurgitation. It has the potential to improve clinical outcomes globally and better serve the needs of this growing patient population.

About Direct Flow Medical, Inc.

Founded in 2004, the Company is headquartered in Santa Rosa, California, and has a second technology and manufacturing facility in Lake Forest, California. The Companys unique implant design is not limited to aortic valve disease but is readily applicable to mitral and other heart valve anatomical sites. Direct Flow Medical has raised 3 rounds of funding to date with the following investors: EDF Ventures, New Leaf Venture Partners, Spray Venture Partners, Foundation Medical Partners, VantagePoint Venture Partners, ePlanet Venture Partners and strategic corporate investors. For further information, please visit the website at http://www.directflowmedical.com.

The Direct Flow Medical Transcatheter Aortic Valve System is an investigation device, limited by applicable law to investigational use and not available for sale.

Link:
Direct Flow Medical® Announces the Appointment of Chief Medical Officer, Charles Davidson, MD

Walgama brothers follow father’s footsteps with careers in medicine

For two Henderson High School graduates, a good dose of medical school runs in the family.

Dr. Evan Walgama graduated from Henderson High School in 2002 and the University of Texas at Austin in 2006.

On June 7, 2010, he graduated from the University of Texas Southwestern Medical School in Dallas, where he is now in his second year of five-year residency program at UT Southwesterns affiliated hospitals.

His focus is in otolaryngology to specialize as an ear, nose and throat doctor.

Evan also graduated with honors and as an Alpha Omega Alpha Honor Medical Society member.

Evans brother, Dr. Jonathan Walgama, is also a Henderson High School graduate in 2003.

In 2007, he graduated from Austin College in Sherman before attending medical school.

On May 21, 2011, Jonathan graduated from Texas A&M Universitys System Health Science Center College of Medicine and, like his brother, received honors as an Alpha Omega Alpha Honor Medical Society member.

Jonathans medical school graduation was unique in that he was hooded by three family physicians during the ceremony, his wife, his brother and his father, his grandfather Dr. Lonnie Traylor said.

The Walgamas father, Dr. U.S. Walgama, still practices in Henderson across from East Texas Medical Center.

View original post here:
Walgama brothers follow father’s footsteps with careers in medicine